New Approaches for Diffuse Large B cell Non Hodgkin Lymphoma Management Strategy | ||
Iraqi Postgraduate Medical Journal | ||
Editorial, Volume 21, Issue 2, April 2022, Pages 131-133 PDF (136.44 K) | ||
DOI: 10.52573/ipmj.2021.174604 | ||
Author | ||
Waseem F. Al Tameemi | ||
Department of Hematology, College of Medicine, Al-Nahrain University, Baghdad, Iraq. Iraqi cultural attaché-Amman, Department of Scholarships and Cultural Relations, Ministry of Higher Education and Scientific Research. Iraq | ||
Abstract | ||
Diffuse large B cell Non Hodgkin lymphoma (DLBCL) is the most frequent subtype, accounts for 30%–40% of cases. The disease is usually aggressive but there is high chance of cure with appropriate treatment lines. | ||
References | ||
10. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 2019; 380:45-56. DOI: 10.1056/NEJMoa1804980
11. Salles G, Duell J, Barca EG , Tournilhac O, W, Liberati AM, et al.Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21:978. https://doi.org/10.1016/S1470-2045(20)30225-4
12. Maerevoet M, Zijlstra JM, Follows G, et al. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. J Hematol Oncol. 2021;14(1):111. Published 2021 Jul 16. doi:10.1186/s13045-021-01122-1
13. Hutchings M, Offner FC, Bosch F, Gritti G, Carlo-Stella C, Walter H, et al. Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma. Blood2020 ; 136, Supplement 1,16-17. https://doi.org/10.1182/blood-2020-136571. | ||
Statistics Article View: 96 PDF Download: 42 |